Treatment of Gram-Negative Bacteremia and Septic Shock with HA-1A Human Monoclonal Antibody against Endotoxin
- 14 February 1991
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 324 (7), 429-436
- https://doi.org/10.1056/nejm199102143240701
Abstract
HA-1A is a human monoclonal IgM antibody that binds specifically to the lipid A domain of endotoxin and prevents death in laboratory animals with gram-negative bacteremia and endotoxemia.Keywords
This publication has 22 references indexed in Scilit:
- Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.Proceedings of the National Academy of Sciences of the United States of America, 1989
- ENDOTOXAEMIA: AN EARLY PREDICTOR OF SEPTICAEMIA IN FEBRILE PATIENTSThe Lancet, 1988
- Effect of High-Dose Glucocorticoid Therapy on Mortality in Patients with Clinical Signs of Systemic SepsisNew England Journal of Medicine, 1987
- A Controlled Clinical Trial of High-Dose Methylprednisolone in the Treatment of Severe Sepsis and Septic ShockNew England Journal of Medicine, 1987
- APACHE IICritical Care Medicine, 1985
- PREVENTION OF GRAM-NEGATIVE SHOCK AND DEATH IN SURGICAL PATIENTS BY ANTIBODY TO ENDOTOXIN CORE GLYCOLIPIDThe Lancet, 1985
- Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies.Proceedings of the National Academy of Sciences of the United States of America, 1985
- Treatment of Gram-Negative Bacteremia and Shock with Human Antiserum to a MutantEscherichia coliNew England Journal of Medicine, 1982
- Gram-negative bacteremia: IV. Re-evaluation of clinical features and treatment in 612 patientsAmerican Journal Of Medicine, 1980
- Limitations of the Usefulness of the Limulus Assay for EndotoxinNew England Journal of Medicine, 1973